TBCOX2 - A phase I/II randomized trial on Safety and Immunogenicity of the Therapeutic H56:IC31 Vaccine and adjunctive Cyclooxygenase-2-inhibitor in patients with Tuberculosis
Date created: | Last Updated:
: DOI | ARK
Creating DOI. Please wait...
Description: This first-in-human randomized clinical trial at Oslo University Hospital, Norway on patients with tuberculosis shows that the vaccine H56:I31 developed by Statens Serum Institut is safe and immunogenic during active tuberculosis disease and could serve as host-directed-therapy to improve prognosis and combat the tuberculosis pandemic